Date published: 2026-7-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

TRAIL CRISPR/Cas9 KO Plasmid (m): sc-423498-KO-2

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • TRAIL CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TRAIL genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TRAIL Antibody (N2B2): sc-56245
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    TRAIL CRISPR/Cas9 KO Plasmid (m)

    sc-423498-KO-2
    20 µg
    $397.00

    Overview

    Tnfsf10 encodes the mouse TNF-related apoptosis-inducing ligand (TRAIL), a type II membrane protein that can be proteolytically released and signals through death receptors to initiate extrinsic apoptosis via FADD-dependent caspase-8 activation. Beyond apoptotic signaling, TRAIL modulates NF-κB and MAPK pathway outputs in a context-dependent manner, influencing inflammatory signaling, cell survival, and immune homeostasis. In mouse models, TRAIL biology is frequently interrogated in studies of tumor immune surveillance, autoimmunity, and tissue injury where death receptor signaling intersects with cytokine networks and stress responses.

    TRAIL CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Tnfsf10 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Tnfsf10 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Tnfsf10 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TRAIL protein expression.

    This CRISPR knockout system enables efficient generation of Tnfsf10-deficient cell models for investigation of TRAIL signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting Tnfsf10 exon(s) critical for TRAIL function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple Tnfsf10 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by TRAIL CRISPR/Cas9 KO Plasmid (m) and TRAIL CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Tnfsf10 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by TRAIL HDR Plasmid (m) and TRAIL HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Tnfsf10 homology arms to support homology-directed repair at defined Tnfsf10 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.